BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 29044505)

  • 21. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.
    Thompson SK; Sullivan TR; Davies R; Ruszkiewicz AR
    Ann Surg Oncol; 2011 Jul; 18(7):2010-7. PubMed ID: 21267790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.
    Christgen M; van Luttikhuizen JL; Raap M; Braubach P; Schmidt L; Jonigk D; Feuerhake F; Lehmann U; Schlegelberger B; Kreipe HH; Steinemann D
    Oncotarget; 2016 Dec; 7(50):82733-82740. PubMed ID: 27716627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.
    Miller CT; Moy JR; Lin L; Schipper M; Normolle D; Brenner DE; Iannettoni MD; Orringer MB; Beer DG
    Clin Cancer Res; 2003 Oct; 9(13):4819-25. PubMed ID: 14581353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB-2 and cyclin D1.
    Mrhalova M; Kodet R
    Neoplasma; 2003; 50(6):396-402. PubMed ID: 14689059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TPD52 represents a survival factor in ERBB2-amplified breast cancer cells.
    Roslan N; Bièche I; Bright RK; Lidereau R; Chen Y; Byrne JA
    Mol Carcinog; 2014 Oct; 53(10):807-19. PubMed ID: 23661506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Amplification and overexpression of c-erbB2 in human breast cancer].
    Chen Y; Dong J; Li C
    Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):16-9. PubMed ID: 7656779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
    Järvinen TA; Tanner M; Bärlund M; Borg A; Isola J
    Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
    König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
    Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma.
    Ooi A; Suzuki S; Nakazawa K; Itakura J; Imoto I; Nakamura H; Dobashi Y
    Anticancer Res; 2009 Jan; 29(1):19-26. PubMed ID: 19331129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
    Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC
    Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
    Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma.
    Andolfo I; Petrosino G; Vecchione L; De Antonellis P; Capasso M; Montanaro D; Gemei M; Troncone G; Iolascon A; Orditura M; Ciardiello F; De Vita F; Zollo M
    BMC Cancer; 2011 Apr; 11():126. PubMed ID: 21481261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
    Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
    Saffari B; Jones LA; el-Naggar A; Felix JC; George J; Press MF
    Cancer Res; 1995 Dec; 55(23):5693-8. PubMed ID: 7585656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amplification of HSD17B1 and ERBB2 in primary breast cancer.
    Gunnarsson C; Ahnström M; Kirschner K; Olsson B; Nordenskjöld B; Rutqvist LE; Skoog L; Stål O
    Oncogene; 2003 Jan; 22(1):34-40. PubMed ID: 12527905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequent amplification of C-erbB2 (HER-2/Neu) oncogene in cervical carcinoma as detected by non-fluorescence in situ hybridization technique on paraffin sections.
    Sharma A; Pratap M; Sawhney VM; Khan IU; Bhambhani S; Mitra AB
    Oncology; 1999; 56(1):83-7. PubMed ID: 9885382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer.
    Dressman MA; Baras A; Malinowski R; Alvis LB; Kwon I; Walz TM; Polymeropoulos MH
    Cancer Res; 2003 May; 63(9):2194-9. PubMed ID: 12727839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.